Pristine Surgical and NexOptic Announce Commercial Agreement To Use AI for Single-Use Surgical Endoscopy Explains NexOptic Ch...
April 07 2021 - 9:15AM
Pristine Surgical LLC and NexOptic Technology Corp. (“NexOptic”)
(TSX VENTURE: NXO) (OTCQB: NXOPF) (FSE: E3O1) announced that they
have entered into an exclusive partnership to deploy NexOptic’s
artificial intelligence (AI) powered imaging technology in
Pristine’s single-use endoscopic visualization platform.
NexOptic’s proprietary neural networks, which power their All
Light Intelligent Imaging Solutions (ALIIS™), are
machine-learning-enabled and allow for more compact, lower-cost,
lighter-weight optics with extreme low-light, anti-glare and data
compression performance. Combined with faster shutter speeds and
reduced motion blur on a variety of platforms, the result is
always-sharper images with a myriad of downstream processing
advantages.
Pristine Surgical’s single-use endoscopes use high-performance
digital image sensors, advanced high-brightness LEDs and powerful
graphics-processing hardware and software to deliver
high-definition, high-quality images in a single-use surgical
endoscope at reduced cost.
The companies will work together to incorporate NexOptic’s Aliis
technology into Pristine’s single-use endoscopic visualization
platform for image optimization.
“At Pristine, we are able to increase patient safety, improve
economics and efficiency and advance the state of the art in
endoscopy by incorporating powerful, cutting-edge technologies in a
single-use visualization platform,” said Bryan Lord, CEO of
Pristine Surgical. “We’re excited to work with NexOptic to use
their ALIIS platform to advance our deployment of artificial
intelligence capabilities and help us further that mission.”
“Pristine has built the endoscopy platform of the future. By
combining our AI expertise with their unique single-use scope
design, there’s an immediate opportunity to further advance the
surgical visualization platform of tomorrow,” added Paul McKenzie,
CEO of NexOptic Technologies. “Today’s announcement is a milestone
for NexOptic’s artificial intelligence imaging solutions. I look
forward to the future and fully anticipate signing additional
clients this year.”
“This is a revolutionary solution that could help millions of
patients annually and ensure surgeons can do their jobs in a safer
manner, and more effectively,” said Rich Geruson, NexOptic
Chairman.About Pristine Surgical
Pristine Surgical LLC is a single-use surgical
visualization company dedicated to improving patient care, safety
and efficacy for the more than 25 million endoscopic (arthroscopy
and laparoscopy) procedures performed worldwide each year.
Pristine’s platform combines high-performance digital image
sensors, advanced high-brightness LEDs and powerful graphics
processing hardware and software with Pristine Connect, a
cloud-based SaaS platform which makes the full surgical episode
more efficient for patient, surgeon and surgery center. Pristine’s
single-use design eliminates the risks posed by
cross-contamination, reduces sterilization and maintenance costs
and provides consistently clear images, every time. Headquartered
in Manchester, N.H., Pristine Surgical is led by an experienced
management team, a seven-person board of managers and a 10-person
medical advisory board. For more information on how we See Beyond™,
visit pristinesurgical.com.
What You Need to Know About ALIIS and
NexOptic Technology Corp.
NexOptic is an innovative imaging AI company
headquartered in Vancouver, Canada with operations in Seoul, South
Korea, offering a world-leading AI platform for imaging known as
ALIIS™ (All Light Intelligent Imaging Solutions). NexOptic
simultaneously influences the optics and AI industries and is a
Preferred Partner in the NVIDIA Partner Network, a member of the
Arm® AI Partner Program, and a member of the Qualcomm® Platform
Solutions Ecosystem. For more information, visit
www.nexoptic.com.
Pristine Surgical ContactsDave CareyGeneral
Manager, MarketingPristine Surgical
LLCdcarey@pristinesurgical.com585.770.0778Brad PerrielloFounder,
Circle Hill Life Science
Communicationsbrad@circlehillcommunications.com617.817.1385
NexOptic Media and Investor
InquiriesLook@nexoptic.com604.669.7330 x 202
NexOptic
SalesAdvantage@nexoptic.comForward-Looking
Statements
This press release contains forward-looking
information and forward-looking statements within the meaning of
applicable securities laws, including, but not limited to,
statements with respect to expectations concerning the development
of the Company’s sports-optic device and technology, and expected
results, specifications, capabilities, and applications thereof.
The reader is cautioned that forward- looking statements are not
guarantees of future performance and involve known and unknown
risks, uncertainties, assumptions, and other factors which are
difficult to predict and that may cause actual results or events to
differ materially from those anticipated in such forward-looking
statements. Forward-looking statements are based on the then
current expectations, beliefs, assumptions, estimates and forecasts
about the business and the industry and markets in which the
Company operates and are qualified in their entirety by the
inherent risks and uncertainties surrounding future expectations,
including, among others: risks commonly associated with the
development of new technologies, including that the Company’s
technology, product designs and prototype are at an early stage and
additional work will be required to confirm potential applications
and feasibility of its technologies or bring product designs to
market; the Company may not be able complete product development as
currently expected; potential applications of the Company’s
technology are based on limited studies and may not be
representative of the broader market; the risk that prototypes and
designs may not achieve expected results; the Company may not be
able to commercialize its technology; the Company may not be able
to source components for its products on a cost-effective basis;
the Company may not have access to necessary financing on
acceptable terms or at all; pending or future patent applications
may not be approved as contemplated or at all; and other risks
inherent with technology and product development and the business
of the Company. Such forward-looking statements should therefore be
construed considering such factors. Other than in accordance with
its legal or regulatory obligations, the Company is not under any
obligation and it expressly disclaims any intention or obligation
to update or revise any forward-looking statements, whether because
of new information, future events, or otherwise.
Neither the TSX Venture Exchange nor its
Regulation Services Provider (as that term is defined in the
policies of the TSX Venture Exchange) accepts responsibility for
the adequacy or accuracy of this news release.
Nexoptic Technology (TSXV:NXO)
Historical Stock Chart
From Mar 2024 to Apr 2024
Nexoptic Technology (TSXV:NXO)
Historical Stock Chart
From Apr 2023 to Apr 2024